Investors & Media

Multiple opportunities for immuno-oncology

Investors Home

Ziopharm Oncology is focused on advancing the next generation of immunotherapies to weaponize the existing immune system with Controlled IL-12 or introduce new immune system elements with Sleeping Beauty-modified T cells to this fight against cancer. In addition to developing the next generation of immuno-oncology medicines that target multiple types of cancers, we also are targeting the cost and complexity of delivering gene and cell therapies.

Events & Presentations

Corporate Contacts:

Christopher Taylor, Vice President,
Investor Relations and Corporate Communications
(617) 502-1881
ctaylor@ziopharm.com